• Police seek suspects in deadly birthday party shooting
  • Lawmakers launch inquires into U.S. boat strike
  • Nov. 29, 2025, 10:07 PM EST / Updated Nov. 30, 2025,…
  • Mark Kelly says troops ‘can tell’ what orders…

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

Oct. 28, 2025, 1:28 PM EDTBy Melanie ZanonaWASHINGTON — Rep. Marjorie Taylor Greene, R-Ga., ripped into the shutdown strategy of her fellow Republicans and White House staff during a heated conference call on Tuesday.Her chief complaint, which she has also aired publicly, is that Republicans are not doing anything to address the looming health care cliff. Some funding for insurance coverage under the Affordable Care Act expires at the end of this year, and many Americans could see their monthly premium costs double or even triple.GOP Rep. Marjorie Taylor Greene says health care is ‘No. 1 issue’ in her district02:51The issue has increased urgency because open enrollment begins on Saturday, Nov. 1, and there are concerns that people may drop their coverage for 2026 if they see a spike in prices.On Tuesday, Greene accused her party of letting the country down, according to a Republican source who was on the conference call. Greene later confirmed the comments herself on X, adding more detail, in the latest sign of a rift between her and her party.Greene has long been one of President Donald Trump’s most vocal backers, but in recent weeks, she’s bucked her party on a number of high-profile issues, including the administration’s strikes on Iran, the conflict in Gaza and its handling of files related to the Jeffrey Epstein case.Not long after Tuesday’s call ended, the Georgia Republican began posting on X and confirming reports that she had reamed out her party leadership and expressed frustration with the White House’s political team.”I said I have no respect for the House not being in session passing our bills and the President’s executive orders. And I demanded to know from Speaker Johnson what the Republican plan for healthcare is,” she wrote.Greene also argued that Republicans’ shutdown strategy has angered the American people and hurt Trump’s popularity, according to the source on the call.She advocated for the Senate to get rid of the filibuster and for the House to come back into the session, this person said, although she also simultaneously argued Republicans need to get outside of Washington to listen to the anger of real Americans. The House has not been in session since Sept. 19, with House Speaker Mike Johnson, R-La., keeping members out of town to put pressure on Senate Democrats to end the shutdown.#embed-20251002-shutdown-milestones iframe {width: 1px;min-width: 100%} Johnson, who was leading the call, pushed back on Greene. He argued that Republicans are working day and night on a health care solution and that conversations on the expiring Affordable Care Act subsidies are ongoing, according to the source on the call.Greene confirmed as much on X, but said she was unsatisfied with his answer.”Johnson said he’s got ideas and pages of policy ideas and committees of jurisdiction are working on it, but he refused to give one policy proposal to our GOP conference on our own conference call. Apparently I have to go into a SCIF to find out the Republican healthcare plan!!!” she wrote, referring to secure areas for reviewing classified material.We’d like to hear from you about how you’re experiencing the government shutdown, whether you’re a federal employee who can’t work right now, a person who relies on federal benefits like SNAP, or someone who is feeling the effects of other shuttered services in your everyday life. Please contact us at tips@nbcuni.com or reach out to us here.Johnson also pushed back on Greene’s call for the Senate to nuke the legislative filibuster, according to a second source on the call. Most legislation requires 60 votes to pass the Senate, but Greene and others have suggested doing away with that rule to allow Republicans to reopen the government themselves. Proponents of keeping the filibuster in place worry that nuking it could come back to bite Republicans the next time Democrats take control of the Senate.Johnson’s office declined to comment.Melanie ZanonaMelanie Zanona is a Capitol Hill correspondent for NBC News.

admin - Latest News - October 28, 2025
admin
15 views 14 secs 0 Comments




Rep. Marjorie Taylor Greene ripped into the shutdown strategy of her fellow Republicans and White House staff during a heated conference call on Tuesday.



Source link

TAGS:
PREVIOUS
Netanyahu orders 'powerful' strikes on Gaza
NEXT
Veteran-led rescue group on standby to evacuate Americans from Jamaica
Related Post
September 28, 2025
Sept. 28, 2025, 5:00 AM EDTBy Berkeley Lovelace Jr.Last winter, Brian Noonan read online that some doctors were prescribing an obscure drug, typically given to cancer patients, for autism. Curious, he looked into it for his son Benjamin, who had just been diagnosed with autism in October.“We jumped on it,” Noonan said. “It felt right and it made sense.”The medication was leucovorin, also called folinic acid. It’s a synthetic form of vitamin B9 or folate, which the body needs to make healthy blood cells. During pregnancy, folate is important to reduce the risk of birth defects.Last Monday, the drug was thrust into the national spotlight by President Donald Trump in a rambling press conference about autism that mainly focused on the president and Health Secretary Robert F. Kennedy’s claim that taking acetaminophen during pregnancy could cause autism. Trump briefly mentioned that an “existing drug” — referring to leucovorin — may help with certain symptoms of autism. For those in the autism community, leucovorin is not new. Dr. Richard Frye, a behavioral child neurologist in Phoenix has studied leucovorin and autism for two decades. He made clear that it is not a cure for autism and that more research is needed. He does, however, prescribe it to some people with autism.Noonan’s son Benjamin, who is 4 years old, is one of Frye’s patients. “He’s higher functioning,” Noonan said. “He’s verbal, but he really struggled to put together sentences.” Since starting on the medicine, the family believes Benjamin’s speech has improved, though he still has difficulties with hyperactivity and impulsiveness.Still, Noonan added, he’s under no impression that the drug is a miracle pill. Benjamin also attends a behavioral program preparing him for kindergarten, Noonan said, and he plans to enroll him in speech and occupational therapy. “We very, very much understand we’re still taking an experimental medication,” he said. The Noonan family. Benjamin, 4, who has autism, has used leucovorin.Courtesy of Brian NoonanOther families say the drug conferred larger benefits.Ben Blomgren, of Minneapolis, said his 11-year-old son, Josh, had been prescribed leucovorin off-label in February after he was at risk of being kicked out of school, even as they tried behavioral modification methods.“He’s pretty severe,” Blomgren said. “He didn’t have any language skills. He was not toilet trained.” After starting the medication, Blomgren said Josh’s sleep improved, he’s fully toilet trained and he’s stopped running away from them. “It wasn’t overnight, but we saw major improvement,” he said. Yomarie Miranda, of Florida, said she saw improvements in her 7-year-old son Ethan after he started the medication, including following instructions in class.Ethan was prescribed the medication off label earlier this month, she said.“He’s now looking at me when I speak with him. He’s talking more than before with complete sentences,” she said.A highly unusual moveThe Food and Drug Administration first approved leucovorin in the 1980s to help reduce the toxic side effects of certain chemotherapy drugs.In the decades since, researchers have also studied whether it might treat cerebral folate deficiency (CFD), a neurological condition that makes it harder for folate to reach the brain. Some children with autism also have cerebral folate deficiency, which neurologists say can affect speech, mood and behavior. Last Monday, the FDA said it planned to update the drug’s label to include that use.But the agency’s decision, experts say, rests on just a handful of small studies. And despite Trump’s endorsement, the maker of the brand-name version, GSK, has yet to submit an application to the agency to change the label. In a statement, GSK said it will be submitting the request to expand the approval to include cerebral folate deficiency, though the statement does not mention autism. (Because leucovorin is already an FDA-approved drug, doctors have been able to prescribe it “off label” for other uses, though insurance may not cover it.) It’s a highly unusual move for the FDA: pushing a drug for chemotherapy side effects as a therapy for autism without a formal submission and limited evidence.“It’s incredibly irresponsible,” said Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School. “For 60-plus years, we’ve counted on the FDA to help patients distinguish between products that work and products that don’t work. And here we saw the FDA making an announcement relying on a summary of unclear data and announcing that they had already decided to approve it.”Alycia Halladay, chief science officer at the nonprofit Autism Science Foundation, was frustrated by the implication that this is a breakthrough in autism research.“It’s not like scientists have just been staring at their belly buttons for 20 years, not looking at autism treatments,” Halladay said in an interview earlier this week. “They have, but the standards have been very high to get [treatments] approved.”Andrew Nixon, a spokesperson for the Department of Health and Human Services, which oversees the FDA, said in a statement: “Analysis across 23 publications from 2009-2024 demonstrated the effectiveness for CFD. Overall, 85% of patients experienced some type of clinical benefit including improved speech/communication capabilities.” Nixon’s statement did not mention autism, and he did not respond to follow-up questions.David Mandell, a psychiatry professor at the University of Pennsylvania, said HHS’ claim that 85% of patients experienced a benefit is a “quite a conceptual leap” because it assumes people with cerebral folate deficiency also have autism.Cerebral folate deficiency “is an extremely rare event, and it is accompanied by symptoms of epilepsy, really severe neurodevelopmental problems and some of those symptoms can look like autism, but it’s not,” he said.“I could not think of a single FDA approval that has such weak evidence in the past 20 years,” Mandell added.Frye, the Phoenix neurologist, estimates up to three-quarters of autistic children have antibodies linked to cerebral folate deficiency, based on his research. Other estimates are much lower: Alycia Halladay, chief science officer at the nonprofit Autism Science Foundation, put the rates at roughly 10% to 30%.The studies on leucovorin are small but look interesting, said Dr. Scott Gottlieb, a former FDA commissioner.“It certainly merits follow up,” Gottlieb said.One of the studies was conducted by Frye: a placebo-controlled trial of more than 40 children with the antibodies, published in Molecular Psychiatry in 2018. It found around two-thirds of kids who got the drug saw improvements in verbal communication after 12 weeks. Others saw no changes. The children all had language impairments, as well as a common type of autism that’s not linked to other neurological diseases.Mandell, however, said the results shouldn’t be taken as evidence.“They claim that in certain subgroups of kids in their already small sample, they find these very large effects,” he said, adding that larger-scale trials that establish clear outcomes ahead of time are needed to verify the results. Kesselheim said it’s important for patients to have access to medications that could have a benefit, especially when there is an unmet medical need. But, he said, there are still a number of unanswered questions.“There is no accurate testing for this,” he said. “What are low folate levels? What are normal folate levels? All of that stuff should be worked out.”Frye said he currently uses two methods to assess whether a child has a folate deficiency: a spinal tap — also known as a lumbar puncture — which involves inserting a needle into the lower back to collect fluid from the spinal cord, and a folate receptor antibody test originally developed for pregnant women that isn’t approved by the FDA for diagnosing folate deficiency in children. Edward Quadros, a research professor at SUNY Downstate Health Sciences University who has worked with Frye studying leucovorin for autism, said parents are already trying the drug, including supplement versions, which aren’t regulated and can be dangerous.“By making the FDA approve it, and reputable pharmaceutical companies manufacturing it and selling it, at least it gives you quality dosing,” Quadros said.Berkeley Lovelace Jr.Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.Aria Bendix contributed.
September 25, 2025
Sept. 24, 2025, 8:47 PM EDTBy Tom Llamas, Marlene Lenthang and Ignacio TorresActing ICE Director Todd Lyons called the shooting Wednesday morning at a Dallas Immigration and Customs Enforcement facility, which killed one detainee and critically wounded two, his “worst nightmare.”For Lyons, who previously worked in a Dallas ICE office, the shooting “really hit home.””Seeing the photos today, some of the bullets were in an office that I used to have there,” he said on “Top Story with Tom Llamas.” “It’s just a horrible feeling. People always ask me what’s the thing that keeps me up at night. It’s the safety of the men and women of ICE.”Follow live updates hereThree detainees were shot when gunfire rang out around 6:40 a.m. Wednesday. One victim died at the scene, and the two others were taken to a hospital with gunshot wounds, Dallas police said. No ICE officers were hurt.”My heart goes out that detainee’s family. We’re charged with their protection, their custody. Nothing like that should happen,” Lyons said.The shooter, who multiple senior law enforcement officials briefed on the investigation identified as Joshua Jahn, had fired from a nearby roof or an elevated position down into the field office’s sally port, ICE said.The shooter was found dead with a self-inflicted gunshot wound, ICE said. A bullet found near the shooter bore messages that were “anti-ICE” in nature, the Dallas office of the FBI said, calling the attack an act of “targeted violence.”Lyons said he learned the shooter fired bullets “indiscriminately,” striking windows and lobby doors, and that the shooter fired upon the sally port, where detainees are brought in. The victims were shot while they were in vehicles, he said.”The detainees weren’t outside a vehicle. The shooter was just shooting at random vehicles inside. They were still hit inside the vehicle,” Lyons said. “There were some brave men and women on the ground that went into those vans, were pulling those detainees out while they’re under fire.”He said the shooting was particularly alarming because it happened in the morning commute hours, near an interstate, apartments and businesses, meaning more people could have been hurt.”This was a targeted attack on ICE, but this really could’ve hurt anyone,” Lyons said.Lyons said there has been an increase in attacks “on ICE officers and agents nationwide.””It’s bad enough the men and women of ICE have to go out there and put themselves in harm’s way, doing their law enforcement mission, but never thinking that in our own facility, our own location, we take sniper fire in a major city,” he said.His message to ICE agents is: “I totally have their back.””My No. 1 mission is making sure they go home to their families every night,” he said.Tom LlamasTom Llamas is a senior national correspondent for NBC News and anchor of “Top Story With Tom Llamas” on NBC News NOW.Marlene LenthangMarlene Lenthang is a breaking news reporter for NBC News Digital.Ignacio TorresIgnacio Torres is a coordinating producer for NBC News.
November 5, 2025
Dozens dead after Typhoon Kalmaegi hits the Philippines
October 1, 2025
Outer Banks homes collapse after dual hurricanes
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved